Takeda seeks 'big data' analytics for rare disease drug discovery
This article was originally published in Scrip
Takeda Development Center Americas – a unit of Takeda Pharmaceutical – is teaming up with big data solutions company BioXcel to research and repurpose assets for use in rare and ultra-rare disease indications.
You may also be interested in...
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.